Retatrutide (LY3437943) has emerged as one of the most extensively studied research peptides of 2026, generating significant interest across metabolic research laboratories worldwide. As the first triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor pathways simultaneously, it represents a notable milestone in incretin-based peptide research.
Important notice: Retatrutide is a research compound intended for laboratory use only. It is not approved by Health Canada, the FDA, or any regulatory body for human consumption.
What Is Retatrutide?
Retatrutide is a synthetic peptide developed by Eli Lilly and Company, structurally engineered as a single-molecule triple receptor agonist. Unlike traditional incretin mimetics that target one or two receptor pathways, Retatrutide is designed to simultaneously activate three distinct receptors involved in glucose regulation and energy homeostasis: the GLP-1 receptor, the GIP receptor, and the glucagon receptor.
The molecule is a 39-amino-acid peptide that incorporates a fatty acid side chain, which extends its circulating half-life to approximately six days in published pharmacokinetic studies.
The Breakthrough Significance
The development of Retatrutide marks a conceptual shift in metabolic peptide research. Earlier generations of incretin research began with single agonists such as Semaglutide (GLP-1 only), followed by dual agonists like Tirzepatide (GLP-1 and GIP). Retatrutide is the first compound of its class to successfully integrate glucagon receptor agonism alongside the two incretin pathways.
Mechanism of Action Across Three Receptor Pathways
GLP-1 Receptor Activation
The GLP-1 receptor is widely distributed across pancreatic beta cells, the central nervous system, and gastrointestinal tissues. Research indicates that GLP-1 agonism stimulates glucose-dependent insulin secretion, slows gastric emptying in animal models, and modulates central appetite signaling pathways.
GIP Receptor Activation
The GIP receptor adds a second layer of incretin activity. Studies suggest that GIP agonism complements GLP-1 action by enhancing insulin secretion and influencing adipose tissue metabolism.
Glucagon Receptor Activation
The addition of glucagon receptor agonism distinguishes Retatrutide from all prior research peptides in this class. Research suggests that controlled glucagon receptor activation increases hepatic fatty acid oxidation and resting energy expenditure.
Phase 2 Trial Results: The 48-Week Data
The published Phase 2 clinical trial data from Eli Lilly, which appeared in the New England Journal of Medicine in 2023, has been widely cited in the research community. In the 48-week trial investigating Retatrutide in study participants with obesity, Phase 2 trials reported a mean body weight reduction of approximately 24% at the highest dose tested (12 mg weekly). This figure has become a reference point in metabolic peptide research.
Secondary endpoints published from the trial included improvements in lipid profiles, blood pressure measurements, and glycemic parameters. These Phase 2 findings have generated substantial follow-up research interest.
Retatrutide vs Tirzepatide vs Semaglutide
Semaglutide is a GLP-1 receptor mono-agonist. Phase 3 trial data reported weight reductions of approximately 15% at 68 weeks in the STEP trials.
Tirzepatide adds GIP receptor activity to GLP-1 agonism. The SURMOUNT-1 Phase 3 trial reported weight reductions of approximately 20.9% at 72 weeks.
Retatrutide, by adding glucagon receptor activity, reported 24% reductions in its 48-week Phase 2 trial — a figure achieved in a shorter timeframe than the earlier compounds.
Current Development Status: Phase 3 Trials
As of 2026, Retatrutide has advanced into Phase 3 clinical trials under Eli Lilly's TRIUMPH program. Until Phase 3 data is published and regulatory review is completed, Retatrutide remains strictly an investigational compound. It is not approved for any clinical or consumer use by Health Canada, the FDA, the EMA, or any other regulatory agency.
Why Retatrutide Is One of the Most-Researched Peptides in 2026
Several factors have converged to make Retatrutide a focal point of peptide research in 2026. First, the magnitude of the Phase 2 results has drawn interest from academic and industry research groups alike. Second, the triple-agonist mechanism opens new lines of investigation into receptor crosstalk, pathway balancing, and downstream metabolic signaling. Third, the peptide's extended half-life makes it a useful tool compound for studying chronic pathway activation in animal models.
Canadian research laboratories, particularly those focused on metabolic disease models, obesity research, and incretin pharmacology, have incorporated Retatrutide into a growing number of preclinical investigations.
Sourcing Research-Grade Retatrutide in Canada
Obtaining research-grade Retatrutide in Canada requires sourcing from suppliers that prioritize purity testing, documented synthesis, and cold-chain handling. Based Peptides provides Canadian research laboratories with access to Retatrutide and other investigational compounds, with each batch supported by analytical documentation. Researchers can Buy Retatrutide in Canada through our catalog, which also includes other widely-studied research peptides such as BPC-157, TB-500, and CJC-1295 DAC.
Considerations for Research Protocol Design
When incorporating Retatrutide into a research protocol, investigators commonly consider the compound's long half-life, the dose-response relationships established in published literature, and the appropriate animal or in-vitro model for their research question. The published Eli Lilly data provides a useful reference framework.
Research Use Only Disclaimer
Retatrutide is a research compound and has not been approved by Health Canada, the FDA, or any other regulatory agency for human consumption, treatment, diagnosis, or prevention of any condition. This article does not constitute medical advice. Retatrutide sold by Based Peptides is for laboratory research use only and is not intended for human or veterinary use.